

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 **E-mail:** office@baishideng.com https://www.wjgnet.com

PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

Manuscript NO: 90593

Title: Management of autoimmune hepatitis induced by hepatitis delta virus

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 00052899
Position: Editorial Board
Academic degree: MD, PhD

Professional title: Professor

Reviewer's Country/Territory: China

Author's Country/Territory: Greece

Manuscript submission date: 2023-12-07

Reviewer chosen by: AI Technique

Reviewer accepted review: 2023-12-19 14:06

Reviewer performed review: 2023-12-19 14:16

Review time: 1 Hour

	[] Grade A: Excellent [Y] Grade B: Very good [] Grade C:
Scientific quality	Good
	[] Grade D: Fair [] Grade E: Do not publish
Novelty of this manuscript	[] Grade A: Excellent [Y] Grade B: Good [] Grade C: Fair [] Grade D: No novelty
Creativity or innovation of this manuscript	[] Grade A: Excellent [Y] Grade B: Good [] Grade C: Fair [] Grade D: No creativity or innovation



7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 **E-mail:** office@baishideng.com https://www.wjgnet.com

Scientific significance of the	[] Grade A: Excellent [Y] Grade B: Good [] Grade C: Fair
conclusion in this manuscript	[] Grade D: No scientific significance
	[] Grade A: Priority publishing [Y] Grade B: Minor language
Language quality	polishing [] Grade C: A great deal of language polishing []
	Grade D: Rejection
Conclusion	[] Accept (High priority) [Y] Accept (General priority)
	[] Minor revision [] Major revision [] Rejection
Re-review	[]Yes [Y]No
Peer-reviewer statements	Peer-Review: [Y] Anonymous [] Onymous
	Conflicts-of-Interest: [] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

The present editorial discussed whether new antiviral treatments for HDV, such as Bulevirtide, or immunosuppressive drugs, are more appropriate for the management of patients with Hepatitis Delta Virus and Autoimmune Hepatitis (AIH). The discussion was insightful and comprehensive.